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B Cell immunity in Solid Organ 
Transplantation
Gonca E. Karahan, Frans H. J. Claas and Sebastiaan Heidt*
Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands
The contribution of B cells to alloimmune responses is gradually being understood in 
more detail. We now know that B cells can perpetuate alloimmune responses in multiple 
ways: (i) differentiation into antibody-producing plasma cells; (ii) sustaining long-term 
humoral immune memory; (iii) serving as antigen-presenting cells; (iv) organizing the 
formation of tertiary lymphoid organs; and (v) secreting pro- as well as anti-inflammatory 
cytokines. The cross-talk between B cells and T cells in the course of immune responses 
forms the basis of these diverse functions. In the setting of organ transplantation, focus 
has gradually shifted from T cells to B cells, with an increased notion that B cells are more 
than mere precursors of antibody-producing plasma cells. In this review, we discuss the 
various roles of B cells in the generation of alloimmune responses beyond antibody 
production, as well as possibilities to specifically interfere with B cell activation.
Keywords: HLA, donor-specific antibodies, antigen presentation, cognate T–B interactions, memory B cells, 
rejection
iNTRODUCTiON
In the setting of organ transplantation, B cells are primarily known for their ability to differentiate 
into long-lived plasma cells producing high affinity, class-switched alloantibodies. The detrimental 
role of pre-existing donor-reactive antibodies at time of transplantation was already described in 
the 60s of the previous century in the form of hyperacute rejection (1). With the introduction of the 
complement-dependent cytotoxicity crossmatch assay by Terasaki and colleagues, the problem of 
hyperacute rejection was largely eliminated (2, 3). In the decades that followed focus shifted toward T 
cells and the prevention of cellular rejection. As a consequence, many drugs have been developed to 
successfully keep T cell immunity in check (4). With T cells largely under control, it is now clear that 
B cells remain important as precursors of antibody-producing plasma cells. However, B cells also give 
rise to humoral immune memory in the form of memory B cells, process and present alloantigens 
to T cells, are involved in ectopic lymphoid follicle formation, and modulate T cell responses by 
secreting cytokines. Reciprocal cognate interactions between T cells and B cells play key roles in the 
generation of alloimmune responses (5) (Figure 1).
In order to understand how B cells contribute to adaptive immune responses, we will first sum-
marize the basics of human B cell development. Afterward, we will focus on the various roles of 
B cells in the setting of solid organ transplantation by antibody production, alloantigen presentation 
Abbreviations: ABMR, antibody-mediated rejection; APC, antigen-presenting cell; APRIL, a proliferation-inducing ligand; 
BAFF, B cell-activating factor; BCR, B cell receptor; Bregs, regulatory B cells; CDC, complement-dependent cytotoxicity; 
CTLA4, cytotoxic T lymphocyte-associated protein 4; DSA, donor-specific antibody; FDC, follicular dendritic cells; GC, 
germinal center; HEV, high endothelial venules; HLA, human leukocyte antigens; Ig, immunoglobulin; MHC, major his-
tocompatibility complex; MPA, mycophenolic acid; PRA, panel reactive antibodies; SCS, subcapsular sinus; TFH, follicular T 
helper cells; Tregs, regulatory T cells.
FigURe 1 | Reciprocal interactions between T cells and B cells. Following B cell receptor-mediated uptake of protein antigens, activated B cells process and 
present antigenic peptides in the context of major histocompatibility complex (MHC) class II on their surface to cognate T cells that recognize the MHC–peptide 
complex through their T cell receptor. Ligation of CD40 ligand and CD28 on T cells to CD40 and CD80/86 on B cells, as well as production of several cytokines 
enable differentiation of both B cells and T cells into effector and memory subsets. While B cells can become isotype-switched antibody-producing plasma cells and 
memory B cells, T cells can become activated as effectors or differentiate into memory T cells to sustain cellular immune responses.
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to T cells, intragraft tertiary lymphoid organ formation, as well 
as immune regulation. Finally, we will discuss new venues in 
interfering with B cell activation.
geNeRATiON OF HUMORAL iMMUNe 
ReSPONSeS iN SeCONDARY LYMPHOiD 
ORgANS
B Cell Development in Bone Marrow
B cells are crucial components of the humoral immune response. 
They participate in eradication of pathogens by their ability to 
differentiate into antibody-producing plasma cells, thereby 
propagating long-term serological immune memory. B cell 
development encompasses a programed set of events that initi-
ate in primary lymphoid organs, which advances to a functional 
maturation stage in secondary lymphoid organs. Development 
and survival of B cells depend on the cell surface expression of 
a functional antigen receptor, namely, the B cell receptor (BCR), 
which is a membrane-bound immunoglobulin (Ig) molecule in 
complex with Ig α/β heterodimer signaling molecules (6). In order 
to generate a functional BCR capable of recognizing a broad range 
of antigens but not self, the gene segments encoding the BCR go 
through rearrangements in the bone marrow, by the assembly of 
variable (V), diversity (D), and joining (J) gene segments at both 
Ig heavy and light chain loci via DNA recombination (7). Newly 
formed B cells that express autoreactive BCRs are modified either 
by receptor editing or deleted by apoptosis. Upon completion of 
receptor editing, immature B cells with an intact BCR on their cell 
surface leave the bone marrow as transitional B cells to further 
continue maturation in the peripheral circulation and secondary 
lymphoid organs (8).
Modifications of the BCR proceed in germinal centers (GCs) 
at later stages of B cell differentiation during T cell-dependent 
immune responses as discussed below. While certain B cell sub-
sets respond to polysaccharide antigens such as non-self blood 
group antigens by producing natural antibodies independent of 
T cell help, responses to protein antigens [e.g., human leukocyte 
antigen (HLA)] develop in the presence of T cell help. Since 
alloimmune responses are generally directed at protein antigens, 
we will focus on T cell-dependent follicular B cell responses.
B Cell Activation in Secondary 
Lymphoid Organs
Secondary lymphoid organs are located at strategic sites 
throughout the body and provide the proper environment for 
T and B cells to come into contact with antigen and interact 
with each other. Both aspects are essential for the generation of 
antibody responses. In lymph nodes, B cells form follicles in the 
cortex just beneath the subcapsular sinus (SCS) of the lymphatic 
vessel, while T cells are localized in the paracortex adjacent to 
B cell follicles. The paracortex contains high endothelial venules 
through which lymphocytes and dendritic cells enter the lymph 
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node (9). Immature naïve B cells continuously circulate through 
the peripheral blood, lymph, and enter secondary lymphoid 
organs in order to gain access into B cell follicles where they can 
complete their maturation and receive further survival signals. 
These naïve B cells home to secondary lymphoid organs through 
chemokines secreted by a network of stromal and follicular 
dendritic cells (FDC) (10–12). If a B cell does not encounter its 
specific antigen it detaches from FDC, leaves the lymph node 
via efferent lymphatics, and continues to recirculate between 
peripheral blood and secondary lymphoid organs (13).
Mature naïve B cells can become activated when their BCR 
engages an intact antigen inside or outside primary B cell follicles. 
While follicular B cells can recognize antigen presented on the 
surface of FDC, small soluble antigens can quickly diffuse from 
SCS into B cell follicles and can directly be recognized by BCRs. 
Large antigens such as immune complexes and viruses can be 
transported to B cell follicles by specialized CD169+ macrophages 
resident at SCS. These macrophages lack phagocytosis ability 
and can present the antigen in its intact form to B cells (14). The 
immunological synapse between antigen-presenting cell (APC) 
and BCR initiates downstream signaling events and rearrange-
ments of the B cell cytoskeleton. Subsequently, B cells that have 
acquired and processed antigen move toward the boundaries of 
T and B cell zones to survey for cognate T cell help. CD4+ T cells 
in interfollicular and paracortical T cell zones initially interact 
with cognate antigen-presenting dendritic cells and subsequently 
increase their ability to migrate to B cell follicles.
A mature naïve B cell requires two signals to become activated: 
the first signal is received through the engagement of its BCR 
with cognate antigen and the second through cognate interac-
tion with CD4+ T cells, termed as follicular helper T cells (TFH). 
Upon receiving T cell help at the T–B cell border, B cells can 
either differentiate into short-lived extrafollicular plasmablasts 
that produce low-affinity IgM antibodies or can proceed to go 
through GC reactions.
gC Reactions
Repositioning of antigen-activated T and B cells from the T–B cell 
zone back to the follicle initiates the GC reaction. During this 
transient reaction, B cells start to proliferate and consequently 
trigger the egress of naïve, circulating B cells from the primary 
follicle. The follicle resolves into light and dark zones harbor-
ing B cells at various levels of cell division. Although the exact 
mechanisms that define the fate of B cells in GC are not entirely 
understood, signaling through the BCR and interactions with TFH 
are known to be essential for their survival and differentiation 
into long-lived plasma cells and memory B cells. B cells present 
antigen to TFH in GCs for the second time during the course of 
the humoral immune response. GC B cells with high-affinity BCR 
appear to be most efficient at antigen uptake, processing, and 
presentation to TFH cells as well as being more prone to survival 
than those with low-affinity BCR. Ligation of peptide/major his-
tocompatibility complex (MHC) class II, CD40, and CD80/86 on 
B cells with the TCR, CD40L, and CD28 on T cells, respectively, 
in the presence of cytokines such as IL-2, IL-4, IL-5, and IL-21 
appear to be crucial (15–17). The activated B cells undergo clonal 
expansion, class switch recombination from IgM to IgG, IgA, or 
IgE and acquire somatic hypermutations in the variable region 
of their BCR (18, 19). Affinity-driven selection enables further 
proliferation and differentiation of B cells with high-affinity BCR 
into long-lived plasma cells and memory B cells (20). While 
long-lived plasma cells preferentially home to the bone marrow, 
memory B cells remain quiescent until re-encounter with antigen 
and recirculate between secondary lymphoid organs and the 
peripheral blood (21, 22). Generation of rapid antibody responses 
following antigen re-challenge requires efficient antigen presenta-
tion by memory B cells to cognate memory TFH. Upon receipt of 
this T cell help, memory B cells rapidly differentiate into plasma 
cells and produce high levels of antigen-specific, mainly IgG type 
of antibodies.
wHY ARe B CeLLS iMPORTANT iN SOLiD 
ORgAN TRANSPLANTATiON?
Solid organ transplantation is a life-saving treatment option for 
patients with end-stage organ failure. The level of genetic dis-
parities at HLA class I and II loci between donor and recipient, 
as well as the ability of the recipient’s immune system to respond 
determine the strength of the immune response to an allograft 
(23–25). Immune responses directed toward mismatched HLA 
evoke both the cellular and the humoral arm of the adaptive 
immune system (26, 27). To prevent immunological rejection 
of the allograft, patients receive life-long immunosuppressive 
treatment. Currently available immunosuppressive regimens are 
centered on T cells and have been successful in curtailing acute 
cellular rejection. Successful treatment of cellular rejection by tar-
geting T cells with immunosuppressive drugs have reduced acute 
rejection rates and hence improved short-term graft survival. It 
is clear that these drugs are insufficient in controlling humoral 
immune responses since antibody-mediated rejection (ABMR) 
is the leading cause of chronic allograft failure (28, 29). A grow-
ing body of evidence suggests that B cells play essential roles in 
alloimmunity besides mediating humoral immune responses. 
Understanding the various functions of B cells and the delicate 
balance between different B cell subsets may facilitate advances 
in B cell-targeting immunosuppressive drug development and 
eventually direct toward understanding the mechanisms involved 
in allograft tolerance.
SigNiFiCANCe OF ANTiBODY 
ReSPONSeS iN SOLiD ORgAN 
TRANSPLANTATiON
Antibodies binding to mismatched HLA (or non-HLA) mol-
ecules on donor endothelial cells initiate a set of signaling events 
leading to recruitment of effector cells to the graft endothelium 
through complement-dependent and -independent pathways. 
This process results in graft thrombosis and eventually a decline 
in allograft function. Clinical studies have shown that both 
pre-existence and de novo production of IgG donor-specific 
antibodies (DSA) are strongly associated with acute and chronic 
allograft injury in kidney, heart, lung, and to some extent, liver 
transplantation (29–34). On the contrary, studies on IgM and 
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IgA DSA did not reveal any isolated effect of these isotypes on 
allograft outcome unless they were co-existent with IgG antibod-
ies (35, 36). This indicates that the above described GC response 
needs to be active for pathological antibody response to occur in 
the setting of organ transplantation.
In accordance with several earlier studies, Loupy et  al. 
found in a large-scale retrospective study on renal transplant 
recipients that patients developing DSA after transplantation 
have inferior 5-year graft survival rates compared to those 
without DSA (37). Among those patients with de novo DSA, the 
capability to fix complement was associated with more severe 
lesions including microvascular inflammation and C4d deposi-
tion. In a recent study, Lefaucheur et al. investigated the role of 
complement fixation of HLA-DSA in a cohort of 635 kidney 
transplant recipients (38). The authors categorized patients into 
three groups: ABMR-free, acute ABMR, and subclinical ABMR. 
They found that whereas ABMR-free patients most prominently 
had IgG1+ DSA lacking C1q fixing capacity, patients with 
acute ABMR most frequently showed IgG3+ DSA, which was 
associated with microvascular inflammation, C4d deposition in 
peritubular capillaries, and inferior graft survival. Interestingly, 
patients classified as having subclinical ABMR showed IgG2+ 
and IgG4+ DSA and had predominantly chronic lesions. 
Results from this study highlight the divergence between acute 
complement-dependent and chronic complement-independent 
roles for HLA-specific antibodies in mediating different types 
of allograft injury.
While circulating antibodies are mainly produced by long-
lived plasma cells residing in the bone marrow, local alloanti-
body production within intragraft tertiary lymphoid organs 
has also been described (39). Thaunat et  al. demonstrated the 
presence of alloantibodies in supernatants of renal cortex tissue 
cultures, suggestive for local antibody production within the 
graft. Comparison of HLA antibody specificities and strength 
of the antibody response revealed differences in serum and 
supernatant samples from the same patient (39). Several stud-
ies have shown the presence of DSA eluted either from core 
needle biopsy samples or explanted renal tissue of patients with 
failed allografts, which may be due to absorbance of circulating 
alloantibodies but may also be pointing toward local produc-
tion (40–42). Huibers et  al. found DSA in lysates of coronary 
arteries of heart allograft autopsies harboring ectopic lymphoid 
structures. Interestingly, DSA and non-DSA found in the graft 
and serum at the time of autopsy were directed only against 
HLA class II (43). A recent study by Milango et al. showed the 
presence of DSA in both serum and graft eluates at the time of 
nephrectomy in the absence of immunosuppressive treatment. 
Although HLA-C and -DP mismatches between the recipients 
and donors were not analyzed, 80% of HLA antibody specificities 
were found to be directed at mismatched donor epitopes both for 
HLA classes I and II (44).
Currently available methods to detect serum HLA (discussed 
elsewhere in this issue of Frontiers in Immunology) do not 
provide any information on the magnitude of HLA-specific 
memory B cells (45). As described above, these memory B cells 
can rapidly differentiate into antibody-secreting cells upon 
re-challenge. Memory B cells exert this rapid function upon 
re-encounter with the immunizing HLA or in response to a non-
specific innate stimuli due to their lower activation threshold 
and constitutive toll-like receptor expression (46–48). Several 
reports have shown the presence of additional HLA antibody 
specificities that are not detected in serum but in the culture 
supernatants of polyclonally activated peripheral blood B cells 
from kidney transplant recipients with a history of sensitization 
(49, 50). Therefore, studying donor-specific B cell responses in 
the transplant setting is certainly of importance, and several 
recently developed techniques allow to do so (51–57).
A ROLe FOR B CeLLS iN ANTigeN 
PReSeNTATiON TO ALLOReACTive 
T CeLLS
Expression of high levels of MHC class II and costimulatory 
molecules on activated B cells, their capacity to take up antigens 
by their BCR, and ability to clonally expand make B cells also 
extremely potent APC (58–64). Nonetheless, the APC function 
of B cells in transplantation setting was initially neglected among 
others due to murine studies reporting efficient CD4+ T cell 
priming in B cell-deficient mice transplanted with skin or cardiac 
allografts (65–67). However, it turned out that the developmental 
absence of B cells may have triggered non-B cell APC to deviate 
T cell responses toward a Th1 phenotype, thereby potentiating 
allograft rejection (68).
In order to assess the role of B cells as APC to alloreactive 
T cells in the transplant setting, Noorchashm et  al. generated 
bone marrow chimeric mice lacking either MHC class II or the 
MHC class II peptide loading machinery, specifically in B cells 
(69). Both of these chimeras showed prolonged cardiac allograft 
survival compared to wild-type controls, which experienced early 
T cell-mediated rejection. These results indicate that antigen 
presentation by B cells is involved in T cell-mediated rejection. 
However, although the authors observed impaired IgG alloanti-
body production in addition to a decreased CD4+ T cell division 
rate, these experiments did not formally answer the question 
whether B cells are required for T cell differentiation into effector 
or memory subsets. This question was addressed by Ng et al. in 
an allogeneic skin transplantation model using B cell-deficient 
(μMT) mice. Whereas similar numbers of IFN-γ producing CD4+ 
and CD8+ T cells compared to wild type were found early after 
transplantation (effector phase), at a later stage (memory phase), 
μMT mice showed decreased numbers of alloreactive IFN-γ+ 
T cells (70). These data suggest that memory T cell development 
is dependent on the interaction with B cells. While these studies 
provided evidence for the contribution of B cells to antigen pres-
entation and T cell differentiation, the impact of alloantibodies 
on transplant outcome was not formally excluded. It appears that 
both alloantibodies and B cell-dependent T cell activation are 
important since Burns and colleagues showed that the enhanced 
T cell-mediated rejection of murine cardiac allografts upon 
 re-challenge is caused by a combined effect of alloantibodies and 
memory B cell-dependent activation of T cells (71).
In clinical kidney transplantation, the possible role for 
B cells as APC in T cell-mediated rejection mainly comes from 
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studies on renal biopsies. A landmark study by Sarwal and col-
leagues showed dense B cell clusters in biopsies of acute cellular 
rejections that did not correlate with C4d deposition but were 
associated with steroid resistance and inferior graft survival 
(72). Since then, several groups confirmed the correlation of 
graft-infiltrating CD20+ B cell clusters with steroid-resistant 
acute cellular rejection and poor graft survival (73–75), whereas 
other investigators did not find any prognostic significance of 
these intragraft B cell clusters neither for treatment sensitivity 
nor for transplant outcome (76–78). Remarkably, CD20+ B cell 
clusters were mainly present in cases of T cell-mediated rejec-
tions without any association to ABMR, which is suggestive 
for a significant role of B cells other than antibody production 
(72–75). Indeed, intragraft CD20+ B cells have been shown to 
display an activated, mature phenotype as shown by CD79a and 
HLA-DR expression and are often found in close proximity to 
CD4+ T cells (75). In an elegant study using cell distance map-
ping, ICOS+CXCR4+ FTH-like cells were found in close proximity 
to B cells in both T cell-mediated or mixed cellular rejection, 
thereby strongly supporting the concept of antigen presentation 
by these B cells to alloreactive T cells (79).
B CeLLS iN TeRTiARY LYMPHOiD 
ORgANS OF CHRONiCALLY ReJeCTeD 
ALLOgRAFTS
Ectopic lymphoid organs resemble canonical secondary lym-
phoid organs regarding their T and B cell compartmentalization 
and interaction with dendritic cells, as well as the utilization 
of chemokine-mediated signaling pathways. By contrast, they 
display impaired lymphatic drainage and therefore trap the 
antigen leading to continuous exposure of immune cells to the 
antigen. De novo formation of lymphoid-like structures as a 
result of persistent antigen exposure at sites of chronic infection 
or inflammation in non-lymphoid organs has been described in 
both autoimmunity and cancer (80, 81).
Upon organ transplantation, an environment containing 
persisting antigen similar to an autoreactive milieu is created 
and as a result can lead to tertiary lymphoid organ formation 
(82). Kerjaschki et al. demonstrated proliferating T cells (75%) 
and B cells (25%) in nodular infiltrates in close proximity with 
lymphatic vessels in explanted kidney allografts (83). Similarly, 
Thaunat et al. described the presence of lymphoid neogenesis in 
virtually all allografts explanted due to chronic rejection (39, 84). 
B cells in these explants were organized into nodules reminiscent 
of either primary or secondary B cell follicles. Relatively high 
expression of genes characteristic for GCs were observed in 
renal secondary B cell follicles indicating a highly activated 
phenotype for graft-infiltrating B cells (39, 85). Furthermore, 
local B cell proliferation, a characteristic for the GC response, 
occurs as shown by Ki67 positivity and clonality of infiltrating 
B cells (83–85). In tertiary lymphoid organs, graft-infiltrating 
B  cells might be contributing to lymphoid angiogenesis by 
prominent expression of vascular endothelial growth factor-
A (86). Organization of the lymphoid infiltrates in the form 
of ectopic GCs may lead to containment of the alloimmune 
response within the graft. The aforementioned absence of DSA 
in circulation or discrepancies in specificities or strength of 
locally produced and circulating HLA antibodies supports this 
hypothesis (39, 84). It is possible that the infiltrates observed 
during acute T  cell-mediated rejection may represent an early 
stage of tertiary lymphoid organ development.
B CeLLS AS iMMUNe RegULATORS
In addition to their roles in immune activation, (subsets of) 
B cells may also have regulatory function (87). Several groups 
have reported B cells with regulatory properties in controlling 
autoimmunity and inflammation (87–90). A complicating fac-
tor in studying regulatory B cells (Bregs) is the lack of a unique 
marker to define these cells. This has resulted in a wide range of 
B cell subsets to be identified as Bregs with the ability to secrete 
IL-10, IL-35, or TGF-β (91–93). In mice, a T cell costimulatory 
molecule termed as T cell Ig domain and mucin domain (TIM1) 
was found to be useful for identifying IL-10-producing Bregs 
(94). In humans, two main subsets of B cells enriched for Bregs 
have been described: CD24hiCD38hi transitional B cells (89) and 
CD24hiCD27+ B10 cells (95). Whereas IL-10, IL-35, and TGF-β 
have all been described as effector molecules of Bregs, in the 
setting of transplantation, the main focus has been on IL-10-
producing B cells.
In transplantation, regulatory functions of B cells have 
mainly been investigated in murine models of allograft toler-
ance. Ding et al., using a mouse model of islet transplantation, 
demonstrated that TIM1 may also have functional properties in 
Breg development. They observed prolonged allograft survival 
in mice treated with an agonistic anti-TIM1 antibody com-
pared to untreated mice (94). Interestingly, in mice depleted of 
B cells before transplantation, anti-TIM1 treatment accelerated 
allograft rejection, indicating an important role for B  cells 
in TIM1-mediated tolerance. Transfer of TIM1+ B cells into 
untreated recipients of islets led to prolonged allograft survival. 
This regulatory effect was defective in TIM1+ B cells, show-
ing the dependency of B cells on IL-10 for their regulatory 
capacity. Shortly after, Lee et  al. reported 100% long-term 
islet  allograft survival in mice treated with a combination 
of anti-CD45RB and TIM1 (96). They demonstrated prompt 
rejection of islet  allografts if regulatory T cells (Tregs) were 
depleted before transplantation, implying that Bregs require 
an interaction with Tregs to induce tolerance. Furthermore, Le 
Texier et al. have shown the presence of intragraft IgM+ B cells 
in rats with cardiac allograft tolerance compared to the presence 
of IgG+ B cells in allografts showing chronic rejection (97), 
suggestive for a restriction in B cell activation in the tolerant 
group. To demonstrate that tolerance was (at least partially) 
caused by B cells, the authors performed adoptive transfer of 
splenic B cells from tolerant rats to show allograft tolerance in 
these secondary mice.
A hint toward a role for B cells in clinical transplantation 
tolerance came from studies identifying B cell signatures in 
operationally tolerant kidney transplant recipients who were 
immunosuppression-free for at least 1 year with stable graft func-
tion (98–100). Microarray analyses on peripheral blood revealed 
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22 B cell-specific genes that were enriched in tolerant patients 
compared to those with stable graft function. Furthermore, the 
CD20 transcript was found to be the only marker higher in urine 
sediments of tolerant patients. Indeed, three genes (IGKV4-1, 
IGLL1, and IGKVID-13) encoding Ig kappa and lambda light 
chains in the course of B cell differentiation were shown to be 
predictive of operationally tolerant patients (98). In an accom-
panying study, six highly overexpressed genes were identified in 
tolerant patients (CD79B, TCL1A, SH2D1B, MS4A1, FCRL1, and 
FCRL2) that were associated with B cell-related pathways (99). 
Interestingly, expression of CD79B, MS4A1, and TCL1A has 
been shown to be significantly downregulated in renal transplant 
recipients with acute rejection (101, 102).
Tolerant patients showed increased peripheral blood B cell 
numbers and a redistribution of B cell subsets toward a naïve 
(IgM+IgD+CD27−) and transitional (CD24hiCD38hi) phenotype 
with increased expression of IL-10, compared to patients with 
stable graft function under immunosuppressive treatment (98, 
99). The findings on IL-10-competent transitional B cells are in 
line with the definition of Bregs as described by Blair et al. (89). 
Pallier and colleagues confirmed the elevated peripheral blood 
B cell numbers and found that B cells with a memory phenotype 
(IgD−CD38−/+CD27+) were increased (103). Whether these 
are the B10 cells as described by the group of Tedder remains 
to be established (95). Compared to patients with stable graft 
function, the majority of the operationally tolerant patients 
do not have circulating DSA and have a lower frequency of 
CD38+CD138+ plasma cells in the peripheral blood (98, 99, 103). 
In order to determine whether there was a defect in tolerant 
patients in generating humoral immune responses, Chesneau 
et al. polyclonally activated purified B cells from operationally 
tolerant patients in vitro. Polyclonally activated B cells prolifer-
ated and produced normal levels of IgM and IgG, accompanied 
by increased levels of IL-10 compared to those with stable 
graft function (104). In order to asses the inhibitory role of 
polyclonally activated B cells of tolerant patients on autologous 
CD4+CD25− T cells, Chesneau et al. blocked IL-10, TGF-β, and 
granzyme B in a T–B cell co-culture system and found that only 
granzyme inhibitors affected the suppressive effects of B cells 
(105). However, antigen specificity, a prerequisite for immune 
regulation, has yet to be demonstrated.
eFFeCTS OF iMMUNOSUPPReSSive 
TReATMeNTS ON B CeLLS
In the current practice of kidney transplantation, standard triple 
immunosuppressive regimen consists of a calcineurin inhibitor 
(tacrolimus or cyclosporine), a purine analog (mycophenolic 
acid-MPA), and corticosteriods as maintenance therapy in 
addition to a non-depleting anti-CD25 monoclonal antibody as 
the induction agent (106). Since these agents exert their effects 
preferentially on T cells, they may abrogate humoral immune 
responses indirectly by inhibiting the T cell help (107), although 
some of these also have a direct effect on B cells (108, 109). 
Drugs specifically interfering with humoral immunity can be 
classified into several groups: drugs that deplete B cells from the 
circulation, those that interfere with T–B cell interaction, drugs 
targeting B cell survival signals, and drugs interfering with anti-
body production or effector function.
Current therapies for (highly) sensitized patients are primar-
ily focused on removal of antibodies before transplantation by 
plasmapheresis, intravenous immunoglobulins, or immunoad-
sorption (110). Addition of rituximab, a humanized murine 
CD20 antibody which depletes circulating CD20+ B cells, to 
desensitization protocols resulted in improved outcomes in 
ABO-incompatible transplantation (111–113). Surprisingly, 
when rituximab was administered to non-sensitized patients as 
induction therapy, a higher rate of acute rejection was observed 
compared to controls (114). In addition to its application in treat-
ment of ABMR (115), administration of rituximab led to success-
ful treatment of steroid-resistant acute cellular rejections (116) 
and resolution of B cell infiltrates in graft (117–120). However, 
in patients experiencing chronic allograft dysfunction, rituximab 
treatment was ineffective in resolution of tertiary lymphoid 
organs despite the successful depletion of circulating B cells (121). 
Kamburova et al. showed long-lasting B cell depletion in patients 
receiving rituximab as induction agent with repopulating B cells 
mainly consisting of transitional B cells (122). Similar results 
were obtained when patients were treated with alemtuzumab, 
an anti-CD52 monoclonal antibody (123, 124). Although poly-
clonal activation of purified B cells did not reveal a difference in 
proliferation or IgM-producing cells, a significant decrease in 
IgG-producing cells was observed (123).
Another way of attenuating B cell responses can be achieved 
by blocking the critical costimulatory pathways between T and 
B cells. A recent study by Chen et al. in a mouse model of cardiac 
allograft transplantation showed that costimulation blockade 
with a high-affinity CTLA-4Ig (belatacept) inhibited memory B 
cell responses and DSA formation, thereby leading to prolonged 
graft survival (125). By blocking both CD28–CD80/86 (belata-
cept) and CD40–CD40L (2C10R4) pathways in a non-human 
primate model of ABMR, Kim et al. showed a decrease in clonal 
B cell expansion in GCs (126). Combined blockade led to reduced 
IL-21 production and was strongly associated with reduced DSA 
levels. Importantly, results of a large phase 3 trial confirmed the 
efficacy of belatacept in the clinical setting (127). This study 
revealed a reduction of DSA in the belatacept-treated group with 
a significant reduced risk of graft loss and death compared to the 
cyclosporine-treated group.
Several studies have shown increased serum levels of B cell-
activating factor (BAFF) following treatment with depleting 
agents in kidney transplant recipients (128, 129), possibly due 
to a lack of BAFF consuming B cells. BAFF has a critical role 
in promoting survival, maturation, and activation of B cells, as 
well as maintaining self-tolerance (130). High levels of BAFF 
have been described in the setting of autoimmunity, and it is 
conceivable that high BAFF levels could also influence alloim-
munity. Indeed, elevated serum BAFF levels were associated with 
increased risk of developing DSA and ABMR in the setting of 
kidney transplantation (131–133). Blockade of BAFF and/or the 
related molecule called a proliferation-inducing ligand (APRIL) 
may be an additional tool to downregulate humoral alloimmune 
responses as was suggested by the prolonged survival of cardiac 
allografts in BAFF-deficient mice (134). Also, in a non-human 
7Karahan et al. B Cell Immunity in Solid Organ Transplantation
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 7 | Article 686
primate ABMR model, BAFF/APRIL blockade (atacicept) was 
able to prevent de novo DSA production (135).
Plasma cells are responsible for the continuous production 
of antibodies and therefore have a high proteasomal activity. 
Proteasome inhibitors, such as bortezomib, are effective for the 
treatment of plasma cell malignancies (136). Bortezomib has 
been used to treat ABMR and diminish DSA production in sen-
sitized transplant recipients (137–140). However, the inhibitory 
capacity of proteasome inhibitors is not limited to plasma cells as 
also naïve and memory B cell proliferation can be affected (141). 
Therefore, antibody production through plasma cells, as well as 
the various effects of B cells, may be dampened by proteasome 
inhibition.
CONCLUSiON AND ReMARKS
B cells contribute to acute and chronic allograft rejection 
processes by producing DSA. More recently, other functions 
have been attributed to B cells that may also influence the 
alloimmune response, such as antigen presentation to T cells, 
formation of tertiary lymphoid organs, or secretion of regula-
tory cytokines.
Considering that one-third of the patients on the kidney 
waiting lists are sensitized as a result of previous exposure to 
allogeneic HLA, memory B cells and their effector functions 
may play central roles in prospective transplantation outcome of 
these patients. Upon re-challenge, HLA-specific memory B cells 
 generated during primary immune responses can promptly 
become high-affinity DSA-producing plasma cells and may 
serve as potent APC by their high expression of HLA-DR 
and costimulatory molecules. In conclusion, a variety of B cell 
populations with different functions may affect the alloimmune 
response after transplantation. Future therapies targeting B cells 
should take into consideration these different functions and 
the consequence that a simple depletion of all B cells will also 
interfere in the beneficial effects of certain B cell subpopulations.
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